• Introducing Alzheimer’s illness associated mind picture evaluation know-how together with Neurophet AQUA and Neurophet SCALE PET
• Plans to launch evaluation know-how for toddler mind picture and cerebrovascular illness

SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ — Neurophet, a man-made intelligence (AI) answer firm for mind illness, introduced on the twenty third that Neurophet would take part within the Radiological Society of North America 2023 (RSNA 2023). Neurophet plans to share the achievements of mind picture evaluation know-how associated to dementia therapies ready over the previous 12 months.

Neurophet will showcase flagship merchandise, mind MRI evaluation software program “Neurophet AQUA” and mind PET scan evaluation software program “Neurophet SCALE PET”. Through the onsite demonstration, attendees might expertise AI-powered mind picture evaluation know-how, which will probably be launched sooner or later comparable to evaluation of Alzheimer’s illness therapy unintended effects.

Alzheimer’s illness therapies comparable to Leqembi, totally accredited by the U.S. Food and Drug Administration (FDA) this 12 months, are new medicine that scale back beta-amyloid proteins within the mind. ARIA (Amyloid-Related Imaging Abnormalities) unintended effects can happen whereas taking the medicine, and the signs embrace edema and hemorrhages. Neurophet plans to launch ARIA evaluation product subsequent 12 months and can introduce the know-how on the sales space as properly.

Neurophet is about to current at AI Theater and Scientific Poster Session based mostly on the research of mind evaluation know-how associated to Alzheimer’s illness. The medical director of Neurophet will give displays on the subject of “How to be Prepared for the Real-World Amyloid Target Drug Prescriptions: ARIA, Amyloid Positivity and Beyond” at AI Theater.

The different examine “White Matter Lesion Asymmetry-An Indicator of Amyloid PET Positivity in Mild Cognitive Impairment Patients” will probably be offered on the Scientific Poster Session.

“Neurophet prepared demonstrations of various technologies to analyze infant brain image and cerebrovascular disease, which will be launched in the future in addition to Alzheimer’s disease at RSNA” mentioned CEO Jake Junkil Been of Neurophet. “Based on Neurophet’s brain image analysis technology encompassing the entire brain disease, we will intensify our efforts in sales and marketing to lead to meaningful business results.”

The RSNA, celebrating its 109th anniversary this 12 months, is the world’s largest radiology society, attracting consultants and officers from academia, drugs, and trade worldwide to share the newest research and achievements. RSNA takes place in Chicago, USA yearly, which begins this 12 months on the twenty sixth (native time) and runs till the thirtieth.

About Neurophet

Neurophet has specialised in growing options for analysis assist, therapy guides, and therapy units concentrating on mind illnesses based mostly on cutting-edge synthetic intelligence (AI) know-how. The firm was based in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system.

Major merchandise embrace mind MRI evaluation software program “Neurophet AQUA”, mind PET scan evaluation (PET tracer deposition) software program “Neurophet SCALE PET”, mind imaging therapy planning software program for electrical and magnetic mind stimulation “Neurophet tES/TMS LAB”, and cloud-based mind imaging evaluation analysis instrument “Neurophet SegPlus”.

Neurophet has set its prime precedence to serving to sufferers affected by mind illnesses. Based on experience in neuroscience, Neurophet will proceed to problem and develop to discover the human mind’s well being and pioneer options for mind illnesses with AI know-how.

View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/neurophet-to-showcase-brain-image-analysis-technology-at-rsna-2023-301996336.html

SOURCE Neurophet